BRINTELLIX Trademark

Trademark Overview

On Monday, March 26, 2012, a trademark application was filed for BRINTELLIX with the United States Patent and Trademark Office. The USPTO has given the BRINTELLIX trademark a serial number of 79114307. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Sunday, March 27, 2022. This trademark is owned by H. Lundbeck A/S. The BRINTELLIX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparation and substances for the prevention and treatment of disorders and diseases in or affecting the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological diseases and disorders; pharmaceutical preparations and substances for the prevention and treatment of Alzheimer's disease, depression, psychosis, anxiety, epilepsy, sclerosis, porphyries, Huntington's disease, insomnia, Parkinson disease, schizophrenia, bipolar disorder, oncology, pain, alcoholism and dependency; diagnostic preparations, substances, reagents and agents for medical purposes
brintellix

General Information

Serial Number79114307
Word MarkBRINTELLIX
Filing DateMonday, March 26, 2012
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateSunday, March 27, 2022
Registration Number4420245
Registration DateTuesday, October 22, 2013
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 27, 2012

Trademark Statements

Goods and ServicesPharmaceutical preparation and substances for the prevention and treatment of disorders and diseases in or affecting the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological diseases and disorders; pharmaceutical preparations and substances for the prevention and treatment of Alzheimer's disease, depression, psychosis, anxiety, epilepsy, sclerosis, porphyries, Huntington's disease, insomnia, Parkinson disease, schizophrenia, bipolar disorder, oncology, pain, alcoholism and dependency; diagnostic preparations, substances, reagents and agents for medical purposes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code1 - Sec. 7(d) - Entire Registration
Class Status DateFriday, May 22, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameH. Lundbeck A/S
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressDK-2500 Valby
DK
Party NameH. Lundbeck A/S
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDK-2500 Valby
DK
Party NameH. Lundbeck A/S
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDK-2500 Valby
DK

Trademark Events

Event DateEvent Description
Sunday, October 16, 2022NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Sunday, October 16, 2022DEATH OF INTERNATIONAL REGISTRATION
Saturday, February 20, 2021TOTAL INVALIDATION PROCESSED BY THE IB
Saturday, January 23, 2021TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Saturday, January 23, 2021INVALIDATION PROCESSED
Friday, January 22, 2021TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, May 22, 2020CANCELLED SECTION 7-TOTAL
Thursday, April 30, 2020CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, March 31, 2020TEAS SECTION 7 SURRENDER RECEIVED
Monday, October 22, 2018COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Thursday, June 12, 2014ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, June 12, 2014TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, February 28, 2014FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, February 11, 2014FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, February 11, 2014FINAL DISPOSITION PROCESSED
Wednesday, January 22, 2014FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, October 22, 2013REGISTERED-PRINCIPAL REGISTER
Friday, September 13, 2013EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, December 18, 2012EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, November 27, 2012OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 27, 2012PUBLISHED FOR OPPOSITION
Monday, November 26, 2012NOTIFICATION PROCESSED BY IB
Wednesday, November 7, 2012NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, November 7, 2012NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, November 7, 2012NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, October 24, 2012LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, October 23, 2012ASSIGNED TO LIE
Wednesday, October 10, 2012APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, October 5, 2012TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 4, 2012CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 4, 2012TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, September 9, 2012REFUSAL PROCESSED BY IB
Friday, July 27, 2012NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, July 27, 2012REFUSAL PROCESSED BY MPU
Friday, July 27, 2012NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, July 26, 2012NON-FINAL ACTION WRITTEN
Tuesday, July 24, 2012APPLICATION FILING RECEIPT MAILED
Thursday, July 19, 2012ASSIGNED TO EXAMINER
Thursday, July 19, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, July 13, 2012LIMITATION FROM ORIGINAL APPLICATION ENTERED
Friday, July 13, 2012SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

brintellix substances pharmaceutical preparations nervous system disease central treatment prevention disorders